abacavir
Antiinfectives for systemic use (J05)US regulatory status: approved.
pharma · Generalized Myasthenia Gravis · Chronic inflammatory demyelinating polyneuropathy (CIDP)
Argenx
argenx
Argenx drug portfolio — 16 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
33 Arch Street, Suite 3201, Boston, MA 02110, US HQ
2008 Founded
2,179 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 33 Arch Street, Suite 3201, Boston, MA 02110, US
- Founded
- 2008
- Employees
- 2,179
- Programs
- 32
- Drugs
- 16
- Patents
- 0
Argenx pipeline
Portfolio lens on 16 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Argenx drug portfolio — 16 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Argenx in public FDA and regional records.
-
Development asset linked to Argenx in public FDA and regional records.
-
Development asset linked to Argenx in public FDA and regional records. Molecular target: IgG receptor FcRn large subunit p51.
- Target
- IgG receptor FcRn large subunit p51
- Mechanism
- IgG receptor FcRn large subunit p51 antagonist
-
efgartigimod alfa
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: IgG receptor FcRn large subunit p51.
- Target
- IgG receptor FcRn large subunit p51
- Mechanism
- IgG receptor FcRn large subunit p51 antagonist
-
US regulatory status: approved.
-
human heterologous liver cells
Alimentary tract and metabolism (A16)Alimentary tract and metabolism (A16) compound in Argenx's portfolio.
-
human normal immunoglobulin
Antiinfectives for systemic use (J06)Antiinfectives for systemic use (J06) compound in Argenx's portfolio. Mechanism: Replacement therapy, immunomodulatory effects.
- Mechanism
- Replacement therapy, immunomodulatory effects
-
Development asset linked to Argenx in public FDA and regional records.
-
Development asset linked to Argenx in public FDA and regional records.
-
Development asset linked to Argenx in public FDA and regional records.
-
Development asset linked to Argenx in public FDA and regional records.
-
Development asset linked to Argenx in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to Argenx in public FDA and regional records.
-
tirzepatide
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Gastric inhibitory polypeptide receptor.
- Target
- Gastric inhibitory polypeptide receptor
- Mechanism
- Glucagon-like peptide 1 receptor agonist